Cargando…
Safety of nintedanib before lung transplant: an Italian case series
Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disease that can only be cured by lung transplantation. Pharmacological agents play a role in preserving lung function and prolonging survival until a suitable donor organ becomes available. However, data on the effects of newer antifibroti...
Autores principales: | Balestro, Elisabetta, Solidoro, Paolo, Parigi, Piercarlo, Boffini, Massimo, Lucianetti, Alessandro, Rea, Federico |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849579/ https://www.ncbi.nlm.nih.gov/pubmed/29564136 http://dx.doi.org/10.1002/rcr2.312 |
Ejemplares similares
-
One‐year clinical experience on the use of Nintedanib in systemic sclerosis
por: Magnani, Luca, et al.
Publicado: (2023) -
Twelve-month effects of everolimus on renal and lung function in lung transplantation: differences in chronic lung allograft dysfunction phenotypes
por: Patrucco, Filippo, et al.
Publicado: (2021) -
Cellular and humoral cytomegalovirus immunity changes in one-year combined prophylaxis after lung transplantation: suggestions from and for clinical practice
por: Solidoro, Paolo, et al.
Publicado: (2020) -
Idiopathic Pulmonary Fibrosis and Lung Transplantation: When it is Feasible
por: Balestro, Elisabetta, et al.
Publicado: (2019) -
Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study
por: Campochiaro, Corrado, et al.
Publicado: (2023)